Xiamen Amoytop Biotech Co Ltd
SSE:688278
Cash Flow Statement
Cash Flow Statement
Xiamen Amoytop Biotech Co Ltd
Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||||||||||||||||
Cash Taxes Paid |
(46)
|
(37)
|
(42)
|
(51)
|
(60)
|
(62)
|
(64)
|
(69)
|
(61)
|
(72)
|
(71)
|
(74)
|
(98)
|
(109)
|
(113)
|
(114)
|
(140)
|
(141)
|
(168)
|
(200)
|
(208)
|
(217)
|
(229)
|
|
Change in Working Capital |
(595)
|
(480)
|
(533)
|
(549)
|
(526)
|
(512)
|
(540)
|
(567)
|
(634)
|
(727)
|
(770)
|
(842)
|
(878)
|
(920)
|
(997)
|
(1 062)
|
(1 149)
|
(1 148)
|
(1 160)
|
(1 281)
|
(1 423)
|
(1 607)
|
(1 730)
|
|
Cash from Operating Activities |
120
N/A
|
100
-17%
|
123
+24%
|
118
-4%
|
121
+3%
|
117
-3%
|
93
-21%
|
136
+46%
|
164
+21%
|
208
+26%
|
235
+13%
|
262
+12%
|
286
+9%
|
287
+0%
|
363
+27%
|
302
-17%
|
262
-13%
|
519
+98%
|
512
-1%
|
569
+11%
|
534
-6%
|
421
-21%
|
431
+2%
|
|
Investing Cash Flow | ||||||||||||||||||||||||
Capital Expenditures |
(30)
|
(39)
|
(45)
|
(56)
|
(62)
|
(92)
|
(119)
|
(135)
|
(161)
|
(163)
|
(191)
|
(212)
|
(215)
|
(240)
|
(219)
|
(205)
|
(273)
|
(244)
|
(288)
|
(328)
|
(267)
|
(284)
|
(251)
|
|
Other Items |
0
|
0
|
0
|
(144)
|
(165)
|
(182)
|
(263)
|
(52)
|
47
|
12
|
79
|
190
|
42
|
34
|
(70)
|
(10)
|
29
|
9
|
(17)
|
(11)
|
(125)
|
(155)
|
(57)
|
|
Cash from Investing Activities |
(29)
N/A
|
(39)
-31%
|
(45)
-16%
|
(200)
-348%
|
(226)
-13%
|
(274)
-21%
|
(382)
-39%
|
(187)
+51%
|
(115)
+39%
|
(151)
-31%
|
(112)
+26%
|
(22)
+80%
|
(173)
-682%
|
(206)
-19%
|
(289)
-41%
|
(215)
+26%
|
(244)
-13%
|
(235)
+3%
|
(306)
-30%
|
(339)
-11%
|
(391)
-15%
|
(439)
-12%
|
(309)
+30%
|
|
Financing Cash Flow | ||||||||||||||||||||||||
Net Issuance of Debt |
0
|
(10)
|
(10)
|
0
|
0
|
(42)
|
(41)
|
0
|
0
|
(8)
|
(9)
|
0
|
0
|
(10)
|
(10)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cash Paid for Dividends |
(6)
|
(4)
|
(3)
|
(3)
|
(13)
|
(13)
|
(13)
|
0
|
(21)
|
(21)
|
(21)
|
0
|
(41)
|
(41)
|
(41)
|
0
|
(87)
|
(87)
|
(87)
|
0
|
(167)
|
(167)
|
(167)
|
|
Other |
(2)
|
(4)
|
(5)
|
332
|
333
|
335
|
335
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(5)
|
(6)
|
(8)
|
(7)
|
(7)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(6)
|
|
Cash from Financing Activities |
(18)
N/A
|
(18)
N/A
|
(18)
-1%
|
319
N/A
|
309
-3%
|
280
-9%
|
281
+0%
|
(56)
N/A
|
(65)
-16%
|
(33)
+49%
|
(34)
-2%
|
(35)
-2%
|
(55)
-58%
|
(56)
-2%
|
(58)
-4%
|
(58)
+0%
|
(104)
-78%
|
(93)
+10%
|
(93)
+0%
|
(93)
-1%
|
(174)
-86%
|
(174)
+0%
|
(173)
+1%
|
|
Change in Cash | ||||||||||||||||||||||||
Effect of Foreign Exchange Rates |
0
|
0
|
0
|
1
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(0)
|
0
|
0
|
0
|
(1)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
Net Change in Cash |
73
N/A
|
43
-41%
|
61
+40%
|
238
+291%
|
205
-14%
|
123
-40%
|
(9)
N/A
|
(109)
-1 068%
|
(17)
+84%
|
23
N/A
|
88
+289%
|
204
+131%
|
58
-72%
|
25
-57%
|
15
-38%
|
29
+86%
|
(86)
N/A
|
190
N/A
|
112
-41%
|
135
+20%
|
(32)
N/A
|
(192)
-501%
|
(51)
+73%
|
|
Free Cash Flow | ||||||||||||||||||||||||
Free Cash Flow |
91
N/A
|
61
-33%
|
79
+29%
|
63
-20%
|
60
-4%
|
25
-58%
|
(26)
N/A
|
0
N/A
|
3
+2 649%
|
45
+1 533%
|
44
-2%
|
50
+14%
|
71
+42%
|
47
-34%
|
144
+209%
|
97
-33%
|
(11)
N/A
|
275
N/A
|
224
-19%
|
241
+8%
|
267
+11%
|
138
-48%
|
179
+30%
|